瑞舒伐他汀对急性冠脉综合征血浆细胞因子水平的影响及临床价值分析

目的探讨瑞舒伐他汀对急性冠脉综合征(ACS)血浆细胞因子的影响。方法 87例ACS患者分为瑞舒伐他汀组44例和阿托伐他汀组43例,其中根据瑞舒伐他汀剂量又分为瑞舒伐他汀20 mg组22例和瑞舒伐他汀10 mg组22例,治疗6月;另选35例在我院体检中心体检的健康人群作为对照组。对比各组血浆炎症细胞因子水平、检测斑块的形状和回声情况、大小、数量和厚度,同时测量分叉内膜厚度(IMT)。结果瑞舒伐他汀20 mg组、瑞舒伐他汀10 mg组在血清肿瘤坏死因子(TNF-α)、白细胞介素6(IL-6)、基质金属蛋白酶(MMP-9)和超敏C-反应蛋白(hs-CRP)水平明显低于阿托伐他汀组(P0.05)。瑞舒伐他汀20 mg组、瑞舒伐他汀10 mg组在斑块厚度、IMT减少方面,明显优于阿托伐他汀组,但瑞舒伐他汀20 mg组与瑞舒伐他汀10 mg组比较未见明显差异。结论 ACS患者早期服用小剂量瑞舒伐他汀可降低血浆细胞因子水平,减轻反应炎症,稳定动脉粥样斑块,从而降低严重心血管病发生率,改善ACS患者的预后。

Effect of rosuvastatin on inflammatory cytokines in the patients with acute coronary syndrome

Objective To explore the clinical effect of rosuvastatin on inflammatory cytokines in the patients with acute coronary syndrome（ACS）. Methods Eighty-seven cases of ACS were divided into rosuvastatin group （44 cases） and atorvastatin group （43 cases）, and the rosuvastatin group was divided into 20 mg group and 10 mg group with 22 cases in each group; another 35 healthy cases from medical examination center were enrolled as control group. The plasma levels of inflammatory cytokines were measured, and the patch shape and echogenicity, size, number and thickness were detected. The level of intima-media thickness （IMT） was measured. Results The levels of TNF-α, IL-6, MMP-9 and hs-CRP in 20 mg group and 10 mg group were significantly lower than those in the atorvastatin group （P〈0. 05）. The patch thickness, IMT were more significantly improved in 20 mg group and 10 mg group than those in atorvastatin group （P〈0. 05）. Conclusions High doses of rosuvastatin can decrease the plasma levels of cytokines, reducing inflammation, stabilizing atherosclerotic plaque, thereby, reducing the incidence of serious heart vascular disease, and improving the prognosis of patients with ACS.